Nucleus Genomics has successfully attracted prominent venture capital backing and strategic investments, raising substantial capital across multiple funding rounds. Key investors supporting its clinical-grade whole-genome sequencing platform include high-profile venture funds and institutional groups such as Founders Fund, Seven Seven Six, One Eight Capital, Rose Street Capital, and strategic corporate participants like Samsung Next.